Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) saw a significant drop in short interest during the month of March. As of March 15th, there was short interest totalling 1,568,110 shares, a drop of 0.6% from the February 28th total of 1,577,132 shares. Currently, 4.0% of the shares of the company are short sold. Based on an average daily volume of 101,913 shares, the days-to-cover ratio is presently 15.4 days.

Shares of ZOM stock opened at $0.31 on Thursday. The stock has a market cap of $57.79 million, a price-to-earnings ratio of -1.72 and a beta of 0.38. Zomedica Pharmaceuticals Corp has a 1 year low of $0.30 and a 1 year high of $2.98.

Hedge funds have recently modified their holdings of the business. Northern Trust Corp purchased a new position in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth about $144,000. BlackRock Inc. grew its holdings in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 9.4% during the third quarter. BlackRock Inc. now owns 1,727,098 shares of the company’s stock worth $3,230,000 after buying an additional 147,828 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6.1% during the third quarter. Vanguard Group Inc now owns 145,747 shares of the company’s stock worth $273,000 after buying an additional 8,381 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 13.3% during the fourth quarter. Geode Capital Management LLC now owns 136,655 shares of the company’s stock worth $168,000 after buying an additional 16,065 shares during the last quarter. Finally, Rhumbline Advisers grew its holdings in shares of Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 56.5% during the fourth quarter. Rhumbline Advisers now owns 46,410 shares of the company’s stock worth $57,000 after buying an additional 16,750 shares during the last quarter. 15.56% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and republished in violation of U.S. & international copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/zomedica-pharmaceuticals-corp-nyseamerican-zom-sees-large-drop-in-short-interest/2922509.html.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Company Profile

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

Further Reading: Why is insider trading harmful?

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.